The Center of Excellence in Environmental Toxicology (CEET) at theUniversity of Pennsylvania School of Medicine has been awarded $2.3million over the next four years to study biological indicators ofexposure to cigarette smoke. The grant is part of the NationalInstitutes of Health new Genes, Environment, and Health Initiative(GEI).
The Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol(R) (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.
It’s already known that a person’s social environment can affect their health, with those who are socially isolated—that is, lonely suffering from higher mortality than people who are not.
Children could have their cholesterol levels tested at about 15 months of age to prevent heart disease later in life, say doctors in a study published on bmj.com today.
Chronic fatigue syndrome, also known as ME (myalgic encephalitis), is linked to a stomach virus, suggests research published ahead of print in Journal of Clinical Pathology.
Researchers at Deakin University have found that diesel exhaust is far more damaging to our health than exhaust from biodiesel, the plant-based fuel.
Patients with end-stage kidney disease treated with high doses of folic acid and B vitamins to lower homocysteine levels did not have improvement in survival or reductions in the incidence of vascular events, according to a study in the Sept. 12 issue of JAMA.
Preliminary findings indicate a heart failure medication used by adults, carvedilol, may not significantly improve heart failure outcomes for children and adolescents, according to an article in the Sept. 12 issue of JAMA.
UCSF scientists are reporting what they say is a significant improvement in the technique for genetically reprogramming mouse cells to their embryonic state, a process that transforms the cells, in essence, into embryonic stem cells.
An analysis of four studies involving more than 14,000 patients found that long-term use of the diabetes drug rosiglitazone (Avandia) increased the risk of heart attack by 42 percent and doubled the risk of heart failure, according to a new report from researchers at Wake Forest University School of Medicine and colleagues. There was no effect on death from cardiovascular causes.